BPC-157, a laboratory-made peptide based on a fragment of a stomach protein, is used by health-focused adults mainly for injury recovery and gut complaints. Its case rests overwhelmingly on animal research; in people, a few small reports without comparison groups exist, and no effect on aging or lifespan has been studied. It remains experimental and loosely regulated; the clearest risks come from unregulated products of uncertain purity, sterility, and dose. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP | <1.0 mg/L | Systemic inflammation baseline |
| ALT and AST | Both <25 U/L | Liver clearance and injury |
| Creatinine and eGFR | eGFR >90 mL/min/1.73 m² | Kidney clearance route |
| CBC | Hemoglobin 14–16 g/dL (men), 13–15 g/dL (women) | Detects anemia or infection |
| Fasting glucose | 75–90 mg/dL | Metabolic baseline |
| PSA (men 40+) | No established functional target; track change from own baseline | Screens for hidden prostate cancer |
| IGF-1 | No established target for this use; track change from own baseline | Growth-signaling context |
| Blood pressure | <120/80 mmHg | Detects nitric oxide–related lowering |
Cadence: Home blood pressure daily during week 1; repeat labs and the pain or function score at 4 weeks and again at 3 months; labs and screening status rechecked before any repeat course, then every 6–12 months while use continues.